Citation Impact
Citing Papers
Cdk4/6 Inhibition Induces Epithelial–Mesenchymal Transition and Enhances Invasiveness in Pancreatic Cancer Cells
2012
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome–Positive Lymphoid Leukemia
2015
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
2015
Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma
2011
The mucin-selective protease StcE enables molecular and functional analysis of human cancer-associated mucins
2019 StandoutNobel
Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
2012
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
The CDK4/6 Inhibitor LY2835219 Overcomes Vemurafenib Resistance Resulting from MAPK Reactivation and Cyclin D1 Upregulation
2014
ERα-Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
2011
Ferroptosis regulation by the NGLY1/NFE2L1 pathway
2022 StandoutNobel
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers
2016
CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic Cancers
2014
Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
2016
Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
2010
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
2018
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
2017
A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis
2019
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
2016
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
2020
Hallmarks of Cancer: The Next Generation
2011 Standout
A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity
2019
Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors
2012
Engineered receptors for soluble cellular communication and disease sensing
2024 StandoutNatureNobel
Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy
2012
TGF-β-Id1 Signaling Opposes Twist1 and Promotes Metastatic Colonization via a Mesenchymal-to-Epithelial Transition
2013
Nedd4 ubiquitylates VDAC2/3 to suppress erastin-induced ferroptosis in melanoma
2020
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
2015
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
2014 Standout
A network modeling approach to elucidate drug resistance mechanisms and predict combinatorial drug treatments in breast cancer
2017
Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
2012
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Enhancing Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
2015
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
A view on drug resistance in cancer
2019 StandoutNature
Prominin2 Drives Ferroptosis Resistance by Stimulating Iron Export
2019
Targeted Therapy for Breast Cancer
2013
Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study
2014
Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB
2015
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
2017 StandoutNobel
Targeting Ferroptosis to Iron Out Cancer
2019 Standout
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
2011
The chemical basis of ferroptosis
2019
Targeting cell cycle and hormone receptor pathways in cancer
2013
Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion
2019
Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications
2022 Standout
Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition
2012
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers
2016
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies
2013
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models
2015
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells
2014
Lung cancer: current therapies and new targeted treatments
2016 Standout
Exogenous Monounsaturated Fatty Acids Promote a Ferroptosis-Resistant Cell State
2019
Synthetic lethality as an engine for cancer drug target discovery
2019
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 Standout
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
2015
Breast cancer genomes — form and function
2010
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Cyclin D as a therapeutic target in cancer
2011
Common genetic variants at the 11q13.3 renal cancer susceptibility locus influence binding of HIF to an enhancer of cyclin D1 expression
2012 StandoutNobel
Broadening horizons: the role of ferroptosis in cancer
2021 Standout
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex
2019
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
2015
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Treatment for the endocrine resistant breast cancer: Current options and future perspectives
2017
Emerging Biological Principles of Metastasis
2017 Standout
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
2015 Standout
Therapeutic Implications of Cellular Heterogeneity and Plasticity in Breast Cancer
2015
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
EMT: 2016
2016 Standout
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
2013
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
2017
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
2016
Role of GPX4 in ferroptosis and its pharmacological implication
2018
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
The role of senescent cells in ageing
2014 StandoutNature
The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis
2019 StandoutNature
Ferroptosis: mechanisms, biology and role in disease
2021 Standout
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
2014
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
The PI3K Pathway in Human Disease
2017 Standout
Ferroptosis, radiotherapy, and combination therapeutic strategies
2021
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
2016 StandoutNobel
Signaling through cyclin D-dependent kinases
2013
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer
2016
Molecular Pathways: CDK4 Inhibitors for Cancer Therapy
2014
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
The Hallmarks of Ferroptosis
2018
Breast Cancer Treatment
2019 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p
2017
Spermidine in health and disease
2018 StandoutScience
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
2016
Molecular Pathways: Adaptive Kinome Reprogramming in Response to Targeted Inhibition of the BRAF–MEK–ERK Pathway in Cancer
2014
Loss of CDKN 2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK 4/6 inhibitor PD 0332991 in melanoma cell lines
2014
The Metabolic Underpinnings of Ferroptosis
2020
Chimeric Antigen Receptor Therapy
2018 Standout
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
2015
Targeting CDK4 and CDK6: From Discovery to Therapy
2015
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
2010
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
2013
CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
2014
Molecular Pathways: Targeting the Cyclin D–CDK4/6 Axis for Cancer Treatment
2015
Precise T cell recognition programs designed by transcriptionally linking multiple receptors
2020 Science
Adaptive Immune Resistance: How Cancer Protects from Immune Attack
2015
Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anticancer Efficacy
2016
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Works of Mohammad Atefi being referenced
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
2014
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
2009
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
2012
Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
2011
Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress
2018
COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors
2013